20 results on '"Fitzmaurice, Paul"'
Search Results
2. Why Is Parkinsonism Not a Feature of Human Methamphetamine Users?
- Author
-
Moszczynska, Anna, Fitzmaurice, Paul, and Ang, Lee
- Abstract
For more than 50 years, methamphetamine has been a widely used stimulant drug taken to maintain wakefulness and performance and, in high doses, to cause intense euphoria. Animal studies show that methamphetamine can cause short-term and even persistent depletion of brain levels of the neurotransmitter dopamine. However, the clinical features of Parkinson's disease, a dopamine deficiency disorder of the brain, do not appear to be characteristic of human methamphetamine users. We compared dopamine levels in autopsied brain tissue of chronic methamphetamine users with those in patients with Parkinson's disease and in a control group. Mean dopamine levels in the methamphetamine users were reduced more in the caudate (-61%) than in the putamen (-50%), a pattern opposite to that of Parkinson's disease. Some methamphetamine users had severely decreased dopamine levels, within the parkinsonian range, in the caudate (up to 97% dopamine loss) but not in the putamen. As the putamen and caudate subserve aspects of motor and cognitive function, respectively, our data suggest that methamphetamine users are not parkinsonian because dopamine levels are not sufficiently decreased in the motor component of the striatum. However, the near-total reduction in the caudate could explain reports of cognitive disturbances, sometimes disabling, in some drug users, and suggests that treatment with dopamine substitution medication (e.g. levodopa) during drug rehabilitation might be helpful.
- Published
- 2004
3. Do glutathione levels decline in aging human brain?
- Author
-
Tong, Junchao, Fitzmaurice, Paul S., Moszczynska, Anna, Mattina, Katie, Ang, Lee-Cyn, Boileau, Isabelle, Furukawa, Yoshiaki, Sailasuta, Napapon, and Kish, Stephen J.
- Published
- 2016
- Full Text
- View/download PDF
4. Brain serotonin transporter in human methamphetamine users
- Author
-
Kish, Stephen J., Fitzmaurice, Paul S., Boileau, Isabelle, Schmunk, Gregory A., Ang, Lee-Cyn, Furukawa, Yoshiaki, Chang, Li-Jan, Wickham, Dennis J., Sherwin, Allan, and Tong, Junchao
- Published
- 2009
- Full Text
- View/download PDF
5. Review: Benzylpiperazine: a drug of abuse?
- Author
-
Johnstone, Alice C., Lea, Rod A., Brennan, Katie A., Schenk, Susan, Kennedy, Martin A., and Fitzmaurice, Paul S.
- Subjects
Benzylpiperazine -- Drug use -- Research -- Health aspects ,Pharmaceuticals and cosmetics industries ,Psychology and mental health ,Drug use ,Research ,Health aspects - Abstract
Byline: Alice C. Johnstone (Envirogenomics Group, Institute of Environmental Science and Research Ltd, Porirua, New Zealand, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Dunedin, [...]
- Published
- 2007
- Full Text
- View/download PDF
6. Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats
- Author
-
Brennan, Katharine A., Carati, Caleb, Lea, Rod A., Fitzmaurice, Paul S., and Schenk, Susan
- Published
- 2009
- Full Text
- View/download PDF
7. N-benzylpiperazine has characteristics of a drug of abuse
- Author
-
Brennan, Katharine A., Lake, Barbara, Hely, Lincoln S., Jones, Karen, Gittings, David, Colussi-Mas, Joyce, Fitzmaurice, Paul S., Lea, Rod A., and Schenk, Susan
- Published
- 2007
- Full Text
- View/download PDF
8. Brain antioxidant systems in human methamphetamine users
- Author
-
Mirecki, Anna, Fitzmaurice, Paul, Ang, Lee, Kalasinsky, Kathryn S., Peretti, Frank J., Aiken, Sally S., Wickham, Dennis J., Sherwin, Allan, Nobrega, José N., Forman, Henry J., and Kish, Stephen J.
- Published
- 2004
9. Why is parkinsonism not a feature of human methamphetamine users?
- Author
-
Moszczynska, Anna, Fitzmaurice, Paul, Ang, Lee, Kalasinsky, Kathryn S., Schmunk, Gregory A., Peretti, Frank J., Aiken, Sally S., Wickham, Dennis J., and Kish, Stephen J.
- Published
- 2004
10. Chemical and physical variations of cannabis smoke from a variety of cannabis samples in New Zealand.
- Author
-
Sheehan, Thomas J., Hamnett, Hilary J., Beasley, Richard, and Fitzmaurice, Paul S.
- Subjects
MARIJUANA ,MEDICAL marijuana ,TOBACCO smoke ,SMOKE ,PARTICULATE matter ,MASS spectrometry - Abstract
Studies have compared the chemical properties of tobacco smoke to those of cannabis smoke, with the objective of identifying the chemical attributes responsible for the mutagenicity and carcinogenicity of cannabis smoke. Comparative studies have included small sample sizes and produced conflicting results. The aim of this study was to assess the major chemical and physical variations of cannabis smoke across a range of cannabis samples of different potencies and origins, sourced from the illegal market in New Zealand. Twelve cannabis samples were studied ranging from 1.0% to 13.4% delta-9-tetrahydrocannabinol (Δ
9 THC) content. A smoking machine was used to smoke "joints" (cannabis cigarettes) and the chemical/physical properties of the smoke assessed. The chemical constituents of the smoke extracts were analysed by gas chromatography/mass spectrometry. A range of different chemical constituents (in addition to Δ9 THC) were identified and their concentrations estimated. Terpenoids were identified as the major variable in cannabis smoke, showing a 40-fold range in total terpenoid content. Analysis of the total particulate matter showed that significantly different levels of particulate matter were produced between the different cannabis samples, ranging from 14.6 to 66.3 mg/g of cannabis smoked. The Δ9 THC delivery efficiency during smoking was also investigated and produced consistent results showing a mean and median of 12.6% and 10.8%, respectively, of the theoretically available Δ9 THC (ranging from 7.2% to 28.0%). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. Is brain gliosis a characteristic of chronic methamphetamine use in the human?
- Author
-
Tong, Junchao, Fitzmaurice, Paul, Furukawa, Yoshiaki, Schmunk, Gregory A., Wickham, Dennis J., Ang, Lee-Cyn, Sherwin, Allan, McCluskey, Tina, Boileau, Isabelle, and Kish, Stephen J.
- Subjects
- *
METHAMPHETAMINE , *NEUROGLIA , *ANIMAL models in research , *BRAIN damage , *DOPAMINE , *NEURONS , *NEUROTOXIC agents , *HEAT shock proteins - Abstract
Abstract: Animal data show that high doses of the stimulant drug methamphetamine can damage brain dopamine neurones; however, it is still uncertain whether methamphetamine, at any dose, is neurotoxic to human brain. Since gliosis is typically associated with brain damage and is observed in animal models of methamphetamine exposure, we measured protein levels (intact protein and fragments, if any) of markers of microgliosis (glucose transporter-5, human leukocyte antigens HLA-DRα [TAL.1B5] and HLA-DR/DQ/DPβ [CR3/43]) and astrogliosis (glial fibrillary acidic protein, vimentin, and heat shock protein-27) in homogenates of autopsied brain of chronic methamphetamine users (n=20) and matched controls (n=23). Intact protein levels of all markers were, as expected, elevated (+28%–1270%, P <0.05) in putamen of patients with the neurodegenerative disorder multiple system atrophy (as a positive control) as were concentrations of fragments of glial fibrillary acidic protein, vimentin and heat shock protein-27 (+170%–4700%, P <0.005). In contrast, intact protein concentrations of the markers were normal in dopamine-rich striatum (caudate, putamen) and in the frontal cortex of the drug users. However, striatal levels of cleaved vimentin and heat shock protein-27 were increased (by 98%–211%, P <0.05), with positive correlations (r=0.41–0.60) observed between concentrations of truncated heat shock protein-27 and extent of dopamine loss (P =0.006) and levels of lipid peroxidation products 4-hydroxynonenal (P =0.046) and malondialdehyde (P =0.11). Our failure to detect increased intact protein levels of commonly used markers of microgliosis and astrogliosis could be explained by exposure to methamphetamine insufficient to cause a toxic process associated with overt gliosis; however, about half of the subjects had died of drug intoxication suggesting that “high” drug doses might have been used. Alternatively, drug tolerance to toxic effects might have occurred in the subjects, who were all chronic methamphetamine users. Nevertheless, the finding of above-normal levels of striatal vimentin and heat shock protein-27 fragments (which constituted 10–28% of the intact protein), for which changes in the latter correlated with those of several markers possibly suggestive of damage, does suggest that some astrocytic “disturbance” had occurred, which might in principle be related to methamphetamine neurotoxicity or to a neuroplastic remodeling process. Taken together, our neurochemical findings do not provide strong evidence for either marked microgliosis or astrogliosis in at least a subgroup of human recreational methamphetamine users who used the drug chronically and shortly before death. However, a logistically more difficult quantitative histopathological study is needed to confirm whether glial changes occur or do not occur in brain of human methamphetamine (and amphetamine) users. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
12. Benzylpiperazine: a drug of abuse?
- Author
-
Johnstone, Alice C., Lea, Rod A., Brennan, Katie A., Schenk, Susan, Kennedy, Martin A., and Fitzmaurice, Paul S.
- Subjects
BIOACTIVE compounds ,ECSTASY (Drug) ,DRUGS of abuse - Abstract
N-benzylpiperazine (BZP) is the active ingredient in recreational 'party' or 'p.e.p.' pills, which are used to provide a stimulant, euphoric effect akin to that of methylenedioxymethamphetamine (NDMA, 'ecstasy'). BZP predominantly affects dopamine neurotransmission in a similar fashion to known 'drugs of abuse', such as methamphetamine and cocaine, which strongly suggests BZP has abuse liability. BZP is illegal in many countries including the United States of America and Australia, yet it remains legal in the United Kingdom, Canada and New Zealand. There has been little research, to date, on the neurological consequences of high dose or chronic exposure of BZP. Here we provide a comprehensive review of the information currently available on BZP and suggest a need for further research into the mechanisms of action, long-term effects and potentially addictive properties of BZP. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Brain antioxidant systems in human methamphetamine users.
- Author
-
Mireki, Anna, Fitzmaurice, Paul, Lee Ang, Kalasinsky, Kathryn S., Peretti, Frank J., Aiken, Sally S., Wickham, Dennis J., Sherwin, Allan, Nobrega, José N., Forman, Henry J., and Kish, Stephen J.
- Subjects
- *
METHAMPHETAMINE , *BRAIN damage , *DOPAMINERGIC neurons , *OXIDATIVE stress , *URIC acid , *SUPEROXIDE dismutase - Abstract
Animal data suggest that the widely abused psychostimulant methamphetamine can damage brain dopamine neurones by causing dopamine-dependent oxidative stress; however, the relevance to human methamphetamine users is unclear. We measured levels of key antioxidant defences [reduced (GSH) and oxidized (GSSG) glutathione, six major GSH system enzymes, copperzinc superoxide dismutase (CuZnSOD), uric acid] that are often altered after exposure to oxidative stress, in autopsied brain of human methamphetamine users and matched controls. Changes in the total (n 1/4 20) meth- amphetamine group were limited to the dopamine-rich caudate (the striatal subdivision with the most severe dopamine loss) in which only activity of CuZnSOD (+ 14%) and GSSG levels (+ 58%) were changed. In the six methamphetamine users with severe (- 72 to ) 97%) caudate dopamine loss, caudate CuZnSOD activity (+ 20%) and uric acid levels (+ 63%) were increased with a trend for decreased () 35%) GSH concentration. Our data suggest that brain levels of many antioxidant systems are preserved in methampheta- mine users and that GSH depletion, commonly observed during severe oxidative stress, might occur only with severe dopamine loss. Increased CuZnSOD and uric acid might reflect compensatory responses to oxidative stress. Future studies are necessary to establish whether these changes are associated with oxidative brain damage in human metham- phetamine users. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
14. Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans.
- Author
-
Sanyal, Suparna, Wintle, Richard F., Kindt, Katie S., Nuttley, William M., Arvan, Rokhand, Fitzmaurice, Paul, Bigras, Eve, Merz, David C., Hébert, Terence E., van der Kooy, Derek, Schafer, William R., Culotti, Joseph G., and Van Tol, Hubert H.M.
- Subjects
DOPAMINE ,CAENORHABDITIS elegans ,CAENORHABDITIS ,CATECHOLAMINES ,NEUROTRANSMITTERS ,BIOGENIC amines - Abstract
Dopamine-modulated behaviors, including information processing and reward, are subject to behavioral plasticity. Disruption of these behaviors is thought to support drug addictions and psychoses. The plasticity of dopaminemediated behaviors, for example, habituation and sensitization, are not well understood at the molecular level. We show that in the nematode Caenorhabditis elegans, a D1like dopamine receptor gene (dop-1) modulates the plasticity of mechanosensory behaviors in which dopamine had not been implicated previously. A mutant of dop-1 displayed faster habituation to nonlocalized mechanical stimulation. This phenotype was rescued by the introduction of a wild-type copy of the gene. The dop-1 gene is expressed in mechanosensory neurons, particularly the ALM and PLM neurons. Selective expression of the dop-1 gene in mechanosensory neurons using the mec-7 promoter rescues the mechanosensory deficit in dop-1 mutant animals. The tyrosine hydroxylase-deficient C. elegans mutant (cat-2) also displays these specific behavioral deficits. These observations provide genetic evidence that dopamine signaling modulates behavioral plasticity in C. elegans. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
15. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
- Author
-
Fitzmaurice, Paul S., Ang, Lee, Guttman, Mark, Rajput, Ali H., Furukawa, Yoshiaki, and Kish, Stephen J.
- Abstract
The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups ( P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance ( P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra-nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
16. Low levels of astroglial markers in Parkinson’s disease: relationship to α-synuclein accumulation.
- Author
-
Tong, Junchao, Ang, Lee-Cyn, Williams, Belinda, Furukawa, Yoshiaki, Fitzmaurice, Paul, Guttman, Mark, Boileau, Isabelle, Hornykiewicz, Oleh, and Kish, Stephen J.
- Subjects
- *
PARKINSON'S disease , *GENETIC markers , *SYNUCLEINS , *ASTROCYTES , *FRONTAL lobe - Abstract
Although gliosis is a normal response to brain injury, reports on the extent of astrogliosis in the degenerating substantia nigra in Parkinson’s disease (PD) are conflicting. It has also been recently suggested that accumulation of nigral α-synuclein in this disorder might suppress astrocyte activation which in turn could exacerbate the degenerative process. This study examined brain protein levels (intact protein, fragments, and aggregates, if any) of astroglial markers and their relationship to α-synuclein in PD and in the positive control parkinson-plus conditions multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Autopsied brain homogenates of patients with PD (n = 10), MSA (n = 11), PSP (n = 11) and matched controls (n = 10) were examined for the astroglial markers glial fibrillary acidic protein (GFAP), vimentin, and heat shock protein-27 (Hsp27) by quantitative immunoblotting. As expected, both MSA (putamen > substantia nigra > caudate > frontal cortex) and PSP (substantia nigra > caudate > putamen, frontal cortex) showed widespread but regionally specific pattern of increased immunoreactivity of the markers, in particular for the partially proteolyzed fragments (all three) and aggregates (GFAP). In contrast, immunoreactivity of the three markers was largely normal in PD in brain regions examined with the exception of trends for variably increased levels of cleaved vimentin in substantia nigra and frontal cortex. In patients with PD, GFAP levels in the substantia nigra correlated inversely with α-synuclein accumulation whereas the opposite was true for MSA. Our biochemical findings of generally normal protein levels of astroglial markers in substantia nigra of PD, and negative correlation with α-synuclein concentration, are consistent with some recent neuropathology reports of mild astroglial response and with the speculation that astrogliosis might be suppressed in this disorder by excessive α-synuclein accumulation. Should astrogliosis protect, to some extent, the degenerating substantia nigra from damage, therapeutics aimed at normalization of astrocyte reaction in PD could be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
17. Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat
- Author
-
Brennan, Katharine A., Colussi-Mas, Joyce, Carati, Caleb, Lea, Rod A., Fitzmaurice, Paul S., and Schenk, Susan
- Subjects
- *
METHAMPHETAMINE , *DRUG administration , *DRUG efficacy , *AMINES , *METABOLITES , *LABORATORY rats , *TISSUES , *DRUG dosage - Abstract
Abstract: A number of studies have shown that exposure to high doses of methamphetamine (MA) is toxic to central dopamine (DA) and serotonin (5-HT) neurons. In most of those studies, however, high doses of MA were experimenter-administered during a short exposure time. Because contingency is a determinant for many effects of drug exposure, the present objective was to investigate the effects of self-administered MA on tissue monoamine levels following a short (24 hours) or longer (7 days) withdrawal period. As previously reported, a noncontingent “binge” high-dose treatment regimen (4 injections of 10 mg/kg MA administered every 2 hours) produced persistent depletion of cortical 5-HT and striatal DA. Effects of self-administered MA (0.1 mg/kg/infusion) were then determined following a 20-day duration where a yoked design was employed such that some rats received MA contingent on an operant lever press and others received either MA or saline dependent on the responses of the contingent rat. Self-administered MA produced a transient striatal DA depletion with a more persistent increase in DA turnover, indicating the presence of some lasting adaptations. Furthermore, the yoked design revealed that there was no effect of contingency on these parameters. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
18. Chemical and physical variations of cannabis smoke from a variety of cannabis samples in New Zealand.
- Author
-
Sheehan TJ, Hamnett HJ, Beasley R, and Fitzmaurice PS
- Abstract
Studies have compared the chemical properties of tobacco smoke to those of cannabis smoke, with the objective of identifying the chemical attributes responsible for the mutagenicity and carcinogenicity of cannabis smoke. Comparative studies have included small sample sizes and produced conflicting results. The aim of this study was to assess the major chemical and physical variations of cannabis smoke across a range of cannabis samples of different potencies and origins, sourced from the illegal market in New Zealand. Twelve cannabis samples were studied ranging from 1.0% to 13.4% delta-9-tetrahydrocannabinol (Δ
9 THC) content. A smoking machine was used to smoke "joints" (cannabis cigarettes) and the chemical/physical properties of the smoke assessed. The chemical constituents of the smoke extracts were analysed by gas chromatography/mass spectrometry. A range of different chemical constituents (in addition to Δ9 THC) were identified and their concentrations estimated. Terpenoids were identified as the major variable in cannabis smoke, showing a 40-fold range in total terpenoid content. Analysis of the total particulate matter showed that significantly different levels of particulate matter were produced between the different cannabis samples, ranging from 14.6 to 66.3 mg/g of cannabis smoked. The Δ9 THC delivery efficiency during smoking was also investigated and produced consistent results showing a mean and median of 12.6% and 10.8%, respectively, of the theoretically available Δ9 THC (ranging from 7.2% to 28.0%).- Published
- 2018
- Full Text
- View/download PDF
19. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine.
- Author
-
Fitzmaurice PS, Tong J, Yazdanpanah M, Liu PP, Kalasinsky KS, and Kish SJ
- Subjects
- Adult, Age Factors, Brain drug effects, Dopamine analysis, Female, Gas Chromatography-Mass Spectrometry, Humans, Male, Uric Acid analysis, Aldehydes analysis, Amphetamine-Related Disorders metabolism, Brain Chemistry drug effects, Malondialdehyde analysis, Methamphetamine toxicity
- Abstract
Animal studies suggest that the widely used psychostimulant drug methamphetamine (MA) can harm brain dopamine neurones, possibly by causing oxidative damage. However, evidence of oxidative damage in brain of human MA users is lacking. We tested the hypothesis that levels of two "gold standard" products generated from lipid peroxidation, 4-hydroxynonenal (one of the most reactive lipid peroxidation aldehyde products) and malondialdehyde, would be elevated in post mortem brain of 16 dopamine-deficient chronic MA users compared with those in 21 matched control subjects. Derivatized aldehyde concentrations were determined by gas chromatography-mass spectrometry. In the MA group, we found significantly increased levels of 4-hydroxynonenal and malondialdehyde in the dopamine-rich caudate nucleus (by 67 and 75%, respectively) and to a lesser extent in frontal cortex (48 and 36%, respectively) but not in the cerebellar cortex. Approximately half of the MA users had levels of 4-hydroxynonenal falling above the upper limit of the control range in caudate and frontal cortex. A subgroup of MA users with high brain drug levels had higher concentrations of the aldehydes. Our data suggest that MA exposure in human causes, as in experimental animals, above-normal formation of potentially toxic lipid peroxidation products in brain. This provides evidence for involvement of oxygen-based free radicals in the action of MA in both dopamine-rich (caudate) and -poor (cerebral cortex) areas of human brain.
- Published
- 2006
- Full Text
- View/download PDF
20. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
- Author
-
Tong J, Fitzmaurice PS, Ang LC, Furukawa Y, Guttman M, and Kish SJ
- Subjects
- Aged, Aged, 80 and over, Brain pathology, Dopamine metabolism, Enzyme Activation physiology, Female, Humans, Male, Middle Aged, Adenylyl Cyclases metabolism, Brain metabolism, Multiple System Atrophy physiopathology, Parkinson Disease physiopathology, Receptors, Dopamine D1 metabolism, Supranuclear Palsy, Progressive physiopathology
- Abstract
The dopamine D(1) receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D(1) receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D(1) receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.